Jim Simons
ASMB icon

Jim Simons’s Assembly Biosciences ASMB Stock Holding History

Jim Simons’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$434K Buy
15,651
+6,411
+69% +$183K ﹤0.01% 2657
2025
Q4 		$314K Sell
9,240
-144,371
-94% -$4.65M ﹤0.01% 2747
2025
Q3 		$3.93M Buy
153,611
+46,090
+43% +$1.01M 0.01% 1637
2025
Q2 		$1.95M Sell
107,521
-5,790
-5% -$76.4K ﹤0.01% 2130
2025
Q1 		$1.08M Buy
113,311
+18,600
+20% +$243K ﹤0.01% 2373
2024
Q4 		$1.49M Buy
94,711
+29,087
+44% +$468K ﹤0.01% 2238
2024
Q3 		$994K Buy
65,624
+10,713
+20% +$163K ﹤0.01% 2451
2024
Q2 		$753K Buy
54,911
+15,451
+39% +$220K ﹤0.01% 2482
2024
Q1 		$525K Buy
39,460
+3,584
+10% +$41.8K ﹤0.01% 2840
2023
Q4 		$353K Sell
35,876
-5,265
-13% -$50.1K ﹤0.01% 2917
2023
Q3 		$437K Sell
41,141
-17,026
-29% -$205K ﹤0.01% 2772
2023
Q2 		$803K Sell
58,167
-5,650
-9% -$69.4K ﹤0.01% 2595
2023
Q1 		$644K Buy
63,817
+21,868
+52% +$369K ﹤0.01% 2737
2022
Q4 		$654K Buy
41,949
+18,432
+78% +$315K ﹤0.01% 2783
2022
Q3 		$463K Buy
23,517
+4,575
+24% +$111K ﹤0.01% 2973
2022
Q2 		$477K Buy
18,942
+7,617
+67% +$175K ﹤0.01% 3187
2022
Q1 		$280K Sell
11,325
-44,594
-80% -$957K ﹤0.01% 3498
2021
Q4 		$1.56M Buy
55,919
+45,036
+414% +$1.48M ﹤0.01% 2344
2021
Q3 		$454K Sell
10,883
-18,770
-63% -$787K ﹤0.01% 2927
2021
Q2 		$1.38M Sell
29,653
-18,458
-38% -$914K ﹤0.01% 2495
2021
Q1 		$2.66M Buy
48,111
+14,778
+44% +$979K ﹤0.01% 2035
2020
Q4 		$2.42M Buy
33,333
+26,142
+364% +$3.07M ﹤0.01% 2005
2020
Q3 		$1.42M Buy
7,191
+1,554
+28% +$391K ﹤0.01% 2314
2020
Q2 		$1.58M Buy
5,637
+1,317
+30% +$307K ﹤0.01% 2311
2020
Q1 		$769K Sell
4,320
-12,692
-75% -$2.72M ﹤0.01% 2551
2019
Q4 		$4.18M Buy
17,012
+6,596
+63% +$1.22M ﹤0.01% 1967
2019
Q3 		$1.23M Sell
10,416
-692
-6% -$105K ﹤0.01% 2512
2019
Q2 		$1.8M Buy
11,108
+8,575
+339% +$1.63M ﹤0.01% 2387
2019
Q1 		$599K Sell
2,533
-1,050
-29% -$266K ﹤0.01% 2868
2018
Q4 		$973K Sell
3,583
-3,250
-48% -$940K ﹤0.01% 2583
2018
Q3 		$3.04M Sell
6,833
-2,734
-29% -$1.28M ﹤0.01% 2075
2018
Q2 		$4.5M Sell
9,567
-4,350
-31% -$2.3M ﹤0.01% 1854
2018
Q1 		$8.21M Sell
13,917
-1,891
-12% -$1.17M 0.01% 1496
2017
Q4 		$8.58M Buy
15,808
+558
+4% +$253K 0.01% 1472
2017
Q3 		$6.39M Buy
15,250
+3,258
+27% +$998K 0.01% 1604
2017
Q2 		$2.97M Buy
11,992
+11,200
+1,414% +$3.15M ﹤0.01% 2036
2017
Q1 		$242K Buy
+792
New +$194K ﹤0.01% 2965
2016
Q2 		– Sell
-2,650
Closed -$160K – 3320
2016
Q1 		$160K Buy
2,650
+1,658
+167% +$111K ﹤0.01% 3142
2015
Q4 		$89K Buy
+992
New +$108K ﹤0.01% 3122
2015
Q3 		– Sell
-963
Closed -$223K – 3150
2015
Q2 		$223K Sell
963
-1,050
-52% -$203K ﹤0.01% 2959
2015
Q1 		$320K Buy
2,013
+408
+25% +$55.2K ﹤0.01% 2746
2014
Q4 		$151K Buy
1,605
+275
+21% +$27.1K ﹤0.01% 2734
2014
Q3 		$131K Buy
1,330
+278
+26% +$24.7K ﹤0.01% 2618
2014
Q2 		$83K Sell
1,052
-1,220
-54% -$86.5K ﹤0.01% 2681
2014
Q1 		$174K Buy
2,272
+460
+25% +$71.7K ﹤0.01% 2640
2013
Q4 		$415K Sell
1,812
-386
-18% -$70.3K ﹤0.01% 2412
2013
Q3 		$381K Sell
2,198
-984
-31% -$151K ﹤0.01% 2395
2013
Q2 		$458K Buy
+3,182
New +$499K ﹤0.01% 2266

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Jim Simons's ASMB Position: Q1 2026 in Review

Jim Simons increased its Assembly Biosciences (ASMB) stake by 69% in Q1 2026, buying an estimated $183K and bringing the position to 15,651 shares worth $434K. The position accounts for ﹤0.01% of the portfolio, ranked #2657.

Jim Simons first reported a position in ASMB in Q2 2013 and has held it in 48 quarters since. The position peaked at $8.58M in Q4 2017. 75 funds tracked by Wall St. Rank hold ASMB as of Q1 2026.

  • Jim Simons held 15,651 shares of Assembly Biosciences worth $434K as of Q1 2026.
  • Jim Simons bought 6,411 Assembly Biosciences shares in Q1 2026, an estimated $183K.
  • Assembly Biosciences made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2657 holding.
  • Jim Simons first reported a position in Assembly Biosciences in Q2 2013 and has held it in 48 quarters since.
  • Jim Simons's Assembly Biosciences position peaked at $8.58M in Q4 2017.
  • 75 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.